SG Americas Securities
OKUR

SG Americas Securities’s OnKure Therapeutics OKUR Stock Holding History

SG Americas Securities’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,210
Closed -$35K – 3526
2023
Q4 		$35K Buy
+2,210
New +$138K ﹤0.01% 2971

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

SG Americas Securities's OKUR Position: Q1 2024 in Review

SG Americas Securities sold out of OnKure Therapeutics (OKUR) in Q1 2024, closing a stake of 2,210 shares — an estimated $35K sold.

SG Americas Securities first reported a position in OKUR in Q4 2023 and held it in 1 quarter. The position peaked at $35K in Q4 2023. 61 funds tracked by Wall St. Rank hold OKUR as of Q1 2024.

  • SG Americas Securities reported no remaining OnKure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • SG Americas Securities sold 2,210 OnKure Therapeutics shares in Q1 2024, an estimated $35K.
  • SG Americas Securities first reported a position in OnKure Therapeutics in Q4 2023 and held it in 1 quarter.
  • SG Americas Securities's OnKure Therapeutics position peaked at $35K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2024.

Based on SG Americas Securities's 13F filing for Q1 2024, filed 6 May 2024.